Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms OLYMPUS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Nov 2019 Results of pooled analysis of six trials (OLYMPUS, ANDES, ALPS, HIMALAYAS, SIERRAS, and ROCKIES) published in the Fibrogen Media Release
    • 08 Nov 2019 Results of pooled cardio-vascular safety analyses from OLYMPUS, ALPS, ANDES, HIMALAYAS, ROCKIES, SIERRAS trials presented in the AstraZeneca media release.
    • 07 Nov 2019 According to an AstraZeneca media release, results from this trial were presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington, D.C., US.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top